Scimago Lab
powered by Scopus
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


eISSN: 1643-3750

This Week Editorial

Editorial: mRNA Vaccines and Future Epidemic, Pandemic, and Endemic Zoonotic Virus Infections

Dinah V. Parums

Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA

Med Sci Monit 2021; 27:e932915

DOI: 10.12659/MSM.932915

ABSTRACT: There have been rapid developments in safe and effective mRNA vaccines for zoonotic infections in the past year. Years of research have made these advances possible, leading to in vitro-transcribed (IVT) mRNA expressing therapeutic proteins. There are several advantages of mRNA vaccines that include their low-cost manufacturing process, large-scale and rapid production, and the ability to modify the vaccines in response to emerging infections and viral variants. The COVID-19 pandemic and successful vaccination programs for SARS-CoV-2 have highlighted the advantages of mRNA vaccines. Also, mRNA vaccines are in development for several other potential pandemic zoonotic infections, including Ebola virus, rabies virus, Zika virus, HIV-1, and influenza. There may also be hope for the control of pandemic avian influenza by the combination of improved and rapid viral genotyping and the rapid development and mass production of mRNA vaccines. This Editorial aims to present a brief overview of how mRNA vaccines may help control and future epidemic, pandemic, and endemic zoonotic virus infections.

Keywords: Vaccines, COVID-19 vaccine, Influenza, Human, Zoonoses, epidemics, Pandemics, Editorial

Published: 2021-05-09



Epidemiology of Influenza Viruses and Viruses Causing Influenza-Like Illness in Children Under 14 Years Old in the 2018-2019 Epidemic Season in Poland

Katarzyna Kondratiuk, Ewelina Hallmann, Katarzyna Łuniewska, Karol Szymański, Lidia Brydak

Department of Influenza Research, National Influenza Center, National Institute of Public Health – National Institute of Hygiene, Warsaw, Poland

Med Sci Monit 2021; 27:e929303

DOI: 10.12659/MSM.929303

BACKGROUND: This study aimed to investigate the epidemiology of influenza viruses and viruses that caused influenza-like disease in children under 14 years of age in the 2018-2019 epidemic season in Poland, and to identify the public health lessons that can be learned.
MATERIAL AND METHODS: Nose and throat swabs were used to obtain samples. The samples were analyzed in the National Influenza Center, Department of Influenza Research at the National Institute of Public Health-National Institute of Hygiene as well as in 16 Voivodship Sanitary Epidemiological Stations across the country. Methods of RNA isolation depended on the laboratory where the isolation was performed. In all laboratories, quantitative polymerase chain reactions were used to determine the influenza virus type as well as the subtype.
RESULTS: The study group was confirmed to be infected with influenza A and B, with influenza A/H1N1/pdm09 as the dominant subtype. Among the age group of children up to 14 years of age, cases of infection with viruses that cause influenza-like disease were also reported. It was noticeable that the largest number of confirmed cases of infection was recorded in the group of the youngest children (0-4 years). In addition, several different variants of co-infection were registered.
CONCLUSIONS: This population study showed that in the 2018-2019 epidemic season in Poland children aged under 14 years were at risk of influenza virus infection and its complications. The presented data support increasing the percentage of children being vaccinated in Poland.

Keywords: Epidemiology, Influenza, Human, Respiratory Syncytial Virus, Human, Influenza A virus, Influenza B virus

Related articles (0)

Coming soon

Published: 2021-05-08


A Review of Recent Research on the Role of MicroRNAs in Renal Cancer

First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi, China (mainland)

Longfei Yang, Xiaofeng Zou, Junrong Zou, Guoxi Zhang

Med Sci Monit 2021; 27:e930639

DOI: 10.12659/MSM.930639

Published: 2021-05-07


Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous ...

Department of Cardiology, UMR INSERM 1295, Toulouse-Rangueil University Hospital, Toulouse University School of Medicine, Toulouse, France

Anthony Matta, Vanina Bongard, Frédéric Bouisset, Dorota Taraszkiewicz, Jean-Pierre Rabès, Jean Ferrières

Med Sci Monit 2021; 27:e928784

DOI: 10.12659/MSM.928784